Tellus Therapeutics develops novel small molecules derived from human maternal breast milk.
Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury.It was founded in 2018 and is based in Hillsborough, North Carolina.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 13, 2022 | Series A | $35M | 1 | Xontogeny | — | Detail |
May 12, 2021 | Seed | $2M | 1 | Xontogeny | — | Detail |